• EWTX

Edgewise Therapeutics shares surge on positive trial results

Edgewise Therapeutics' stock rose 21% after positive Phase 2 trial results for sevasemten in Becker muscular dystrophy, highlighting functional stabilization and plans for regulatory discussions.